Fact Sheet: Phase III Safety and Efficacy Trial of the RTS,S Malaria Vaccine Candidate
- Publisher:
- GlaxoSmithKline Biologicals
- Publication Date:
- 18 October 2011
- Tags:
- Africa, Malaria, Health and Medicine
The launch of the Phase III efficacy trial of the RTS,S malaria vaccine candidate marked an important milestone after more than 20 years of research and development. The trial started in May 2009 and is now underway at 11 sites in seven African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania). Together, the 11 sites completed enrolment in January 2011, with 15,460 infants and young children participating, making this the largest malaria vaccine trial to date.
Aiming to Eliminate Malaria in Africa
- No One Should Die From Malaria, Say Experts
- A Third of Malaria Affected Countries on Course for Elimination
- PHOTOESSAY: Eliminating Malaria in Africa
- Malaria on the Continent Can Be Eliminated
- Indoor Spraying Still Viable
- Aidspan Reviews an Academic Study On the Effect of Investment in Malaria Control On Child Mortality
